RAAS inhibition and beyond-cardiovascular medications in patients at risk of or affected by COVID-19
Description
The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide. Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs)
